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High levels of pro-inflammatory cytokines and nitric
oxide are proposed to orchestrate pathophysiologic
mechanism(s) associated with various inflammatory
dermatoses. This study examines whether a water sol-
uble 3-O-[N-acetylmuramyl-L-lysyl-D-iso]-2-di-on-gly-
cine [MDP(Lysyl)GDP], a nontoxic and nonpyrogenic
derivative of muramyl dipeptide (MDP), can inhibit
the in vitro production of inflammatory mediators by
lipopolysaccharide- or interferon-g-activated macro-
phages, and whether such an inhibitory effect can translate
into in vivo protection of mice from irritant and allergic
contact dermatitis. Thioglycollate-elicited peritoneal
macrophages cultured in medium alone or in medium
supplemented with MDP(Lysyl)GDP (1–100 mg per ml)
expressed neither mRNA transcripts for inducible nitric
oxide synthase, interleukin-1b, and tumor necrosis factor-
a, nor cytokine proteins and nitric oxide activity. Incuba-
tion of the cells with either lipopolysaccharide or inter-
feron-g for 6 h resulted in a significant induction of
inducible nitric oxide synthase, interleukin-1b, and tumor
There is increasing evidence that pro-inflammatory cyto-kines and nitric oxide (NO) participate in the initiationof allergic and inflammatory processes (Sauder, 1990;Kondo et al, 1994; Mossalayi et al, 1994; Dugas et al,1995; Morita et al, 1996; Werfel et al, 1996). It is well
established that after an antigen challenge or an inflammatory insult,
mast cell-derived mediators such as histamine and serotonin induce
vasodilatation and increase permeability of blood vessels resulting in
edema formation and swelling (Askenase et al, 1983). In dinitrofluoro-
benzene induced hypersensitivity response, for example, expression of
mRNA transcripts for interleukin (IL)-1β, IL-6, IL-10, and granulo-
cyte-macrophage colony stimulating factor are detected in the epidermis
(Kondo et al, 1994). In such a setting, keratinocytes, Langerhans
cells (Heufler et al, 1992; Schreiber et al, 1992), macrophages, and
Manuscript received July 22, 1997; revised February 6, 1998; accepted for
publication March 20, 1998.
Reprint requests to: Dr. Melita Zunic, Novartis Forschungsinstitut, Brunner
Str. 59, A-1235 Vienna, Austria.
Abbreviations: iNOS, inducible nitric oxide synthase; MDP, muramyl dipept-
ide; MDP(Lysyl)GDP, 3-O-[N-acetylmuramyl-L-lysyl-D-iso]-2-di-on-glycine;
NO, nitric oxide.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
77
necrosis factor-a mRNA, and the accumulation of high
levels of monokines and nitrites in cultures by 24 h. Co-
incubation of the macrophages with lipopolysaccharide
or interferon-g and MDP(Lysyl)GDP (1–100 mg per ml)
resulted in a concentration-dependent suppression of the
steady-state mRNA transcripts for inducible nitric oxide
synthase, tumor necrosis factor-a, and interleukin-1b,
induced by lipopolysaccharide, but not by interferon-g.
In mouse models of phorbol ester- and oxazolone-
induced ear inflammation, topical application of
MDP(Lysyl)GDP significantly suppressed ear swelling in
a dose-dependent manner. Likewise, oral treatment with
MDP(Lysyl)GDP at days –3, –2, and –1 before elicitation
with oxazolone also significantly inhibited ear inflamma-
tion. Taken together, our findings suggest that MDP(Lys-
yl)GDP has the potential to be a therapeutic application
in the treatment of inflammatory conditions in which
overproduction of pro-inflammatory mediators are
implicated to play a pathogenic role. Key words: contact
dermatitis/NO. J Invest Dermatol 111:77–82, 1998
lymphocytes (Zachariae et al, 1991; Matsue et al, 1993) are thought to
contribute, in part, to the induced pathology through their local
production of increased amounts of cytokines in the epidermis.
Similarly, in atopic dermatitis expression of the Th1 cytokine, interferon
(IFN)-γ, was proposed to perpetuate the chronic eczematous skin
lesions (Werfel et al, 1996; Thepen et al, 1996). There is also increasing
evidence that implicates NO as a potential mediator of the immunologic
and inflammatory reactions seen in several dermatoses (Morita et al,
1996; Qureshi et al, 1996). Taken together, the dominant role of
proinflammatory mediators in both acute and chronic inflammation
suggests that inhibition of their production can be a novel approach
to treating such disorders.
Safe and effective therapies are needed for inflammatory skin
diseases. Several established effective topical and systemic treatments
for dermatitis are available; however, all of them suffer from more or
less severe adverse effects and some have additional inconvenient
aspects that restrict their use (Breathnach, 1992; Hay et al, 1992;
Mihatsch and Wolff, 1992; Robertson and Maibach, 1992). Potential
candidates that lack the limitations of the steroids are a number of
nontoxic and nonpyrogenic muramyl dipeptide (MDP) derivatives.
Recent studies have demonstrated that these molecules can downregul-
ate ongoing, anamnestic IgE responses in an isotype-specific manner
(Auci et al, 1993). Furthermore, MDP was found to suppress the
78 ZUNIC ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
constitutive gene expression of IL-4, TNF-α, and IL-1β in various
mouse tissues, 6–24 h following oral administration (Zunic et al, 1996).
More recently, Kricek et al (1997) showed that a lipophilic muramyl
peptide derivative, MDP(Threonyl)GDP, suppressed polyclonally
induced IgE responses in anti-IgD-treated mice. In addition, anti-
inflammatory and hepatoprotective activities of other derivatives of
MDP have also been observed in an experimental model of acute
hepatitis (Bahr et al, 1996). The efficacy of MDP derivatives in such a
model was attributed to the downregulation of inflammatory cytokines.
Therefore, the potential use of nontoxic, nonpyrogenic derivatives of
MDP as a novel prophylactic or therapeutic agent in the management
of allergic/inflammatory disorders warrants more investigation.
The aim of this study was to evaluate the potential anti-inflammatory
effect of 3-O-[N-acetylmuramyl-L-lysyl-D-iso]-2-di-on-glycine
[MDP(Lysyl)GDP], a muramyl peptide using in vitro models of produc-
tion of proinflammatory mediators by activated macrophages and
animal models of irritant and allergic contact dermatitis. Our findings
suggest that the nontoxic and nonpyrogenic MDP(Lysyl)GDP probably
exerts its protective effects against phorbol ester- and oxazolone-
induced ear inflammation through the suppression of proinflammatory
mediators release, as suggested from the in vitro studies using activated
macrophages.
MATERIALS AND METHODS
Animals Female BALB/C mice (6–8 wk old) and Crl:NMRI BR mice (10–
12 wk old) were purchased from Charles River (Sulzfeld, Germany). The
animals were housed in a conventional facility under standardized conditions
(room temperature 22 6 1°C; relative humidity 55 6 5%; eight air changes
per h; 12 h day/night cycle) in Makolon cages type III on wood granulate
bedding in groups. The animals had free access to standard laboratory animal
chow and drinking water. They were used after an adaptation period of at least
10 d for harvesting peritoneal macrophages (BALB/C) or for induction of
allergic contact dermatitis and irritant contact dermatitis (Crl:NMRI BR).
Animal procedures were approved by local authorities (MA58–3536/96; MA56–
3658/96).
Cell culture reagents, medium, and chemicals MDP(Lysyl)GDP is a
nontoxic and nonpyrogenic derivative of MDP synthesized at Novartis For-
schungsinstitut (Vienna, Austria) as described elsewhere.1 For in vitro experiments,
the compound was dissolved in RPMI 1640 (Gibco Life Technologies, Paisley,
U.K.) supplemented with 5% or 10% heat-inactivated fetal calf serum (Gibco
Life Technologies). Penicillin, streptomycin, L-glutamine, 2-mercaptoethanol,
lipopolysaccharide (LPS) from Escherichia coli serotype 055:B5, oxazolone, and
dexamethasone were purchased from Sigma (St. Louis, MO). Recombinant
mouse IFN-γ, IL-1β, TNF-α, and IL-10 enzyme linked immunosorbent assay
kits were obtained from Genzyme (Boston, MA). RPMI 1640 was supplemented
with penicillin (100 U per ml), streptomycin (100 µg per ml), 2 mM L-
glutamine, and 0.05 mM 2-mercaptoethanol.
Cell cultures Thioglycollate-elicited macrophages were obtained as reported
previously (Lam et al, 1992). Peritoneal lavage was performed using 10 ml of
cold RPMI containing 5% fetal calf serum. The macrophages were washed
twice with the same medium and 2 3 106 cells per 2 ml were cultured in 24
well plates (Nunc) with or without LPS (10 µg per ml for evaluation of mRNA
and 10 ng per ml for cytokine proteins and nitrites), recombinant murine IFN-
γ (10 U per ml), and MDP(Lysyl)GDP (1–100 µg per ml) at 37°C in 5% CO2
in an air humidified atmosphere for 6 and 24 h.
Preparation of RNA and northern blot analysis Each assay used 2 3 106
macrophages cultured in 24 well plates for preparation of total RNA. Six hours
after incubation of the cells with the indicated stimuli, total cellular RNA was
extracted using 1.5 ml of RNA NOW solution (Biogentex, Seabrook, TX) as
described by the supplier. Samples of total RNA (10 µg) were separated on a
1% agarose, 2.2 M formaldehyde gel and subsequently blotted onto N-Hybond
membrane with 203sodium citrate/chloride buffer by capillary transfer. The
RNA was fixed onto the membrane using UV Stratalinker 1800 (Stratagene,
CA). The filters were prehybridized for 4 h at 65°C in a solution containing
53sodium citrate/chloride buffer, 103Denhart’s solution, 6% sodium dodecyl
sulfate, 10 µg salmon sperm DNA per ml, and 10 µg poly (A) (Boehringer,
Mannheim, Germany) per ml. Hybridization was carried out at 65°C for 16 h
in prehybridization buffer containing 10% dextran sulfate (Sigma) and (α-32P)
1Patent application, WO 9518146, The European Patent Office, NL.
dATP (3000 Ci per mmol; Amersham, U.K.)-labeled synthetic oligonucleotide
probes specific for either inducible nitric oxide synthase (iNOS), 59-CAA CCC
GAG CTC CTG GAA CCA CTC GTA CTT GGG 39; TNF-α, 59-GTC
CCC CTT CTC CAG CTG GAA GAC TCC TCC 39; IL-1β, 59 GCT CAT
GTC CTC ATC CTG GAA GGT CCA CGG 39; or β-actin, 59 CAT CGG
AAC CGC TCG TTG CC 39. After hybridization, blots were washed at 65°C
for 30 min in a solution containing 33sodium citrate/chloride buffer, 5%
sodium dodecyl sulfate, 103Denhart’s solution, and 20 mM sodium phosphate,
and for a second time with a solution containing 13sodium citrate/chloride
buffer and 1% sodium dodecyl sulfate. The filters were exposed to Kodak
XAR-5 X-ray film at –70°C using intensifying screens. Depending on the
signal intensity, exposure times varied between 1 h and 3 d.
Assay of TNF-a, IFN-g, IL-1b, and IL-10 proteins After incubation for
24 h, the supernatants were collected and centrifuged at 10,0003g for 3 min.
Aliquots of culture supernatants were assayed for TNF-α, IFN-γ, IL-1β, and
IL-10 by an enzyme linked immunosorbent assay kit.
Nitrite determination Twenty-four hours after stimulation, the accumula-
tion of nitrite (NO2
–), a stable metabolite of NO, in cell culture supernatants
was assayed by the standard Griess assay (Green et al, 1982). Briefly, 50 µl
aliquots of culture supernatants were reacted with 100 µl amounts each of 1%
sulfanilamide and 0.1% of N-(1-naphthyl)ethylenediamine dihydrochloride in
2.5% phosphoric acid in 96 well tissue culture plates and incubated for 10 min
at room temperature. The absorbance at 540 nm was measured in an automated
enzyme linked immunosorbent assay reader. Nitrite was quantitated by compar-
ison with a NaNO2 standard curve. Results are expressed as µM NO2– per 106
cells per 24 h.
Animal model of irritant contact dermatitis in mice Tetra-
decanoylphorbol-13-acetate (TPA, Sigma)-induced irritant contact dermatitis
was initiated by the topical application of 10 µl 0.01% TPA (in dimethylsulfoxide-
:acetone, 1:99, vol/vol) to the inner surface of the right ears of groups of eight
mice. For topical treatment, the test area was treated with 10 µl of the
compounds or the vehicle DAE 244 (dimethylacetamide:acetone:ethanol, 2:4:4,
vol/vol/vol) 30 min before the irritation. The left ears remained without
irritation and treatment. Identical treatment was performed with dexamethasone
as a positive control. For systemic treatment, the compound was dissolved in
water and given by gavage (50 mg per kg), once daily on days 3, 2, and 1
before irritation. Control animals were treated with water. The animals were
sacrificed and the ears cut off under standardized conditions 6 h after the
application of the irritant. The inflammation was assessed as the increase in ear
weight (Raederstorff et al, 1996; Staite et al, 1996; Meingassner et al, 1997).
The efficacy of MDP(Lysyl)GDP was calculated as percentage inhibition of
inflammation relative to vehicle-treated groups.
Mouse model of contact hypersensitivity to oxazolone (allergic contact
dermatitis) Groups of eight female Crl:NMRI BR mice were sensitized on
the shaved abdomen with 100 µl oxazolone (Sigma, 2% in acetone). After 7 d,
they were challenged with 10 µl of an oxazolone solution (2% for topical
testing and 0.5% for systemic testing) on the inner surface of the right ear. The
unchallenged ears served as controls. Twenty-four hours after challenge, the
difference in pinnal weights was determined as a measure of the inflammation.
For topical treatment, 10 µl of the dissolved MDP(Lysyl)GDP in the concentra-
tion of 33, 100, and 330 µg per ear (1.6, 5, and 16.5 mg per kg) or the
vehicle (ethylacetamide:acetone:ethanol; 2:4:4 vol/vol/vol) was applied at the
challenged site once, 30 min after the challenge. Identical treatment was
performed with dexamethasone as a positive control. Systemic treatment was
given by a daily oral dose of 50 mg per kg (aqueous solution) on days 3, 2,
and 1 before the challenge. Control animals were treated similarly topically or
orally with the vehicle. The efficacy of MDP(Lysyl)GDP and dexamethasone
was assessed as described for the irritant contact dermatitis model.
Statistical analysis Results from in vitro experiments were compared by
using Student’s t test for paired samples and expressed as mean 6 SD. For
allergic contact dermatitis and irritant contact dermatitis, results were compared
by using either parametric tests (ANOVA and Dunnett test) or nonparametric
tests (H- and U-test).
RESULTS
MDP(Lysyl)GDP inhibited the induction of cytokine mRNA in
macrophages activated by LPS but not in cells activated by
IFN-g To investigate the effect of MDP(Lysyl)GDP on LPS and
IFN-γ induced cytokine gene transcript levels in murine peritoneal
macrophages, northern blot analysis of total RNA was performed using
oligonucleotide probes specific for β-actin, iNOS, TNF-α, and IL-1β.
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Figure 1. MDP(Lysyl)GDP downregulated LPS-induced iNOS, TNF-
a, and IL-1b mRNA in macrophages. Murine elicited peritoneal
macrophages were cultured for 6 h with or without LPS (10 ng per ml), IFN-
γ (10 U per ml), MDP(Lysyl)GDP (1–100 µg per ml), and their combinations.
Cytokine gene expression in macrophages was investigated by northern blot
analysis, as described in Materials and Methods. Lane 1, control; lane 2, LPS; lane
3, IFN-γ; lane 4, MDP(Lysyl)GDP, 1 µg per ml; lane 5: MDP(Lysyl)GDP, 10 µg
per ml; lane 6, MDP(Lysyl)GDP, 100 µg per ml; lane 7, LPS 1 MDP(Lysyl)GDP,
1 µg per ml; lane 8, LPS 1 MDP(Lysyl)GDP, 10 µg per ml; lane 9, LPS 1
MDP(Lysyl)GDP, 100 µg per ml; lane 10, IFN-γ 1 MDP(Lysyl)GDP, 1 µg per
ml; lane 11, IFN-γ 1 MDP(Lysyl)GDP, 10 µg per ml; lane 12, IFN-γ 1
MDP(Lysyl)GDP, 100 µg per ml.
As shown in Fig 1, β-actin expression was unaffected in all tested
groups, whereas significant levels of mRNA for iNOS and TNF-α
were induced in the cells activated by LPS or by IFN-γ after 6 h.
Induction of the IL-1β gene occurred only in cells activated by LPS,
but not by IFN-γ. Under identical conditions, MDP(Lysyl)GDP (1–
100 µg per ml) alone did not induce iNOS, TNF-α, and IL-1β
mRNA; however, coculture of MDP(Lysyl)GDP (1–100 µg per ml)
with LPS resulted in a pronounced inhibition of the induction of IL-
1β mRNA at a concentration as low as 1 µg per ml. MDP(Lysyl)GDP
also inhibited the induction of iNOS and TNF-α but at a concentration
of 100 µg per ml. The inhibitory effect of MDP(Lysyl)GDP appeared
to be specific to LPS-induced effects and was not due to cell toxicity.
Support for this notion was provided by the synergy observed between
MDP(Lysyl)GDP and IFN-γ in inducing the expression of macrophage
iNOS and TNF-α genes.
MDP(Lysyl)GDP suppressed the release of cytokines in culture
supernatants by LPS-activated macrophages Macrophages
incubated with MDP(Lysyl)GDP (1–100 µg per ml) or in medium
alone for 24 h did not release detectable amounts of cytokines into
culture supernatants. Activation of the macrophages by LPS resulted
in a significant release of IL-1β, TNF-α, IL-10, and IFN-γ in culture
supernatants (Fig 2a–d). Again, coculture of the cells with both LPS
and MDP(Lysyl)GDP inhibited the release of IL-1β protein dose
dependently with complete inhibition detected at 10 µg per ml of
MDP derivative (Fig 2d). The release of TNF-α by LPS-activated
macrophages was downregulated by MDP(Lysyl)GDP at 100 µg per
ml (Fig 2a). A similar inhibitory effect of MDP(Lysyl)GDP on the
release of IL-10 was also observed at the concentration of 1 µg per ml
and at 100 µg per ml the secretion of IL-10 was completely blocked
(Fig 2c). The inhibition of LPS-stimulated IFN-γ production by
MDP(Lysyl)GDP was less than the inhibition of IL-10, TNF-α, or
IL-1β but was, nevertheless, still statistically significant at 100 µg per
ml (p , 0.05).
MDP(Lysyl)GDP inhibited nitrite, a stable metabolite of NO,
accumulation in culture supernatants of LPS-activated
macrophages Expression and activity of iNOS were monitored by
estimating nitrite, the stable end-product of NO production. Incubation
of the macrophages with MDP(Lysyl)GDP (1–100 µg per ml) alone
did not induce detectable amounts of nitrite in culture supernatants,
whereas incubation of the cells with LPS (10 ng per ml) induced high
levels of nitrite (Fig 2a, b). Co-culture of the macrophages with both
LPS and MDP(Lysyl)GDP resulted in a significant suppression of nitrite
generation. When the cells were either first pretreated with the
compound before activation with LPS (p , 0.001) or MDP(Lysyl)GDP
was added at the same time with LPS, inhibition of nitrite production
occurred at a concentration of 10 µg per ml. In both cases, inhibition
of nitrite production by MDP(Lysyl)GDP was complete at a concentra-
tion of 50 µg per ml (p , 0.001). Incubation of the cells with IFN-γ
(10 U per ml) also resulted in the generation of nitrite in culture
supernatants (Fig 2c). Interestingly, MDP(Lysyl)GDP, like LPS, synerg-
ized dose dependently with IFN-γ in the production of nitrites
(p , 0.001). The synergistic effect of LPS and IFN-γ on the nitrite
production is shown in Fig 2(d). Simultaneously added MDP(Lys-
yl)GDP at a concentration of 50 µg per ml inhibited the accumulation
of nitrites induced by LPS and IFN-γ (p , 0.001). When the cells
were pretreated with 1 µg MDP(Lysyl)GDP per ml for 1 h, and then
restimulated with LPS and IFN-γ, the accumulation of nitrite was
blocked (p , 0.001).
MDP(Lysyl)GDP suppressed ear inflammation caused by phor-
bol ester or oxazolone To evaluate the potential in vivo effect of
MDP(Lysyl)GDP, ear edema was induced by painting the ears of
normal mice with a solution of phorbol ester. The compound (33,
100, and 330 µg per ear) and the vehicle were applied to the ears
30 min prior to the induction of contact irritation. The data in
Table II show that topical application of MDP(Lysyl)GDP resulted in a
significant dose-dependent suppression of ear inflammation (p , 0.001).
Oral administration of the compound (50 mg per kg) on days 3,
2, and 1 prior to TPA challenge produced no effect on the ear
inflammation.
The anti-inflammatory effect of MDP(Lysyl)GDP was also examined
in oxazolone-induced ear inflammation. In this model, mice were
sensitized with oxazolone on the shaved abdomen. Seven days later,
contact hypersensitivity was elicited by applying the hapten onto the
ears. The anti-inflammatory effect of topically applied MDP(Lysyl)GDP
(33, 100, and 330 µg per ear) was examined 30 min after hapten
application. The efficacy of this treatment was assessed 24 h later. As
shown in Table III, ear inflammation was suppressed significantly
(p , 0.001) and in a dose-dependent manner. Similar protection
was observed when the sensitized animals were treated orally with
MDP(Lysyl)GDP (50 mg per kg) on days 3, 2, and 1 prior to
elicitation of contact hypersensitivity with oxazolone (p , 0.001).
Dexamethasone, used as a positive control, effectively suppressed ear
inflammation in a dose-dependent manner (Tables II, III).
DISCUSSION
It has been clearly established that excessively produced proinflammat-
ory cytokines and mediators such as NO play major roles in the
pathophysiologic mechanisms associated with inflammatory dermatoses
(Kolb and Kolb-Bachofen, 1992; Koprowsky et al, 1993; Kondo et al,
1994; Morita et al, 1996; Werfel et al, 1996). The NO-dependent
pathway has been further implicated not only as a generator of toxic
reactive nitrogen intermediates, but also as a major inducer of the
production of other potent pro-inflammatory cytokines, such as IL-6
and TNF-α (Eigler et al, 1993; Becherel et al, 1994; Andrew et al,
1995; Zinetti et al, 1995). Consequently, there is increased interest in
approaches to inhibit the NO pathway as a potential therapeutic target
for treating inflammatory and allergic diseases. In this paper, we present
experimental data showing that MDP(Lysyl)GDP, a nontoxic and
nonpyrogenic derivative of MDP, is a potential anti-inflammatory and
anti-allergic agent.
We have examined the in vitro anti-inflammatory effect of MDP(Lys-
yl)GDP using activated macrophages as a model for the production of
primary inflammatory mediators. The use of these cells, rather than T
cells, is justified on the ground that these cells are known to be cellular
targets for MDP and its derivatives (Wahl et al, 1979; Silverman et al,
1985; Tenu et al, 1989). Moreover, activated macrophages, besides T
cells, are reported to play a critical role in contact hypersensitivity
through their massive release of potent pro-inflammatory mediators
(Kurimoto et al, 1994; Cua et al, 1995; Ahlfors et al, 1996; Tsuji et al,
1997). With this in vitro model, we confirmed that MDP(Lysyl)GDP
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Figure 2. MDP(Lysyl)GDP concentration
dependently downregulates LPS induced
TNF-a, IFN-γ, IL-10, and IL-1b
production in macrophages. Supernatants
from peritoneal macrophages incubated in 24
well plates for 24 h at 37°C with or without
LPS (10 ng per ml) and/or MDP(Lysyl)GDP
(1–100 µg per ml) were assayed for TNF-α (a),
IFN-γ (b), IL-10 (c), and IL-1β (d) levels using
cytokine specific enzyme linked immuno-
sorbent assay kits (Genzyme). Experiments were
performed on three separate occasions. Mean
values are shown with line-scatters 6 SD.
Table I. MDP(Lysyl)GDP modulates nitrite accumulation
induced by LPS, IFN-g, and LPS 1 IFN-g
Simultaneous
Pre-treatmenta additionb
Modulating agent (µg per ml) (nitrite, µM)c (nitrite, µM)
Control, vehicle 0 6 0 0 6 0
MDP(Lys)GDP (1) 0 6 0 0 6 0
MDP(Lys)GDP (10) 0 6 0 0 6 0
MDP(Lys)GDP (50) 0 6 0 0 6 0
MDP(Lys)GDP (100) 0 6 0 0 6 0
LPS 4 6 0.7 7.5 6 3.5
LPS 1 MDP(Lys)GDP (1) 3 6 4 5.5 6 7.7
LPS 1 MDP(Lys)GDP (10) 1.5 6 2 ** 4 6 5.6
LPS 1 MDP(Lys)GDP (50) 0 6 0 ** 0.8 6 1 **
LPS 1 MDP(Lys)GDP (100) 0 6 0 ** 0.2 6 0.3 **
IFN-γ 2 6 1.4 1 6 1.4
IFN-γ 1 MDP(Lys)GDP (1) 1 6 1.4 0.5 6 0.7
IFN-γ 1 MDP(Lys)GDP (10) 12 6 0.3 *** 0.5 6 0.7
IFN-γ 1 MDP(Lys)GDP (50) 15 6 3 *** 10 6 8 ***
IFN-γ 1 MDP(Lys)GDP (100) 20 6 8 *** 14 6 5.6 ***
LPS 1 IFN-γ 29 6 0.6 31 6 0.7
LPS 1 IFN-γ 1 MDP(Lys)GDP (1) 0 6 0 ** 31 6 1.4
LPS 1 IFN-γ 1 MDP(Lys)GDP (10) 0.5 6 0.7 ** 32 6 1.4
LPS 1 IFN-γ 1 MDP(Lys)GDP (50) 9.5 6 2 ** 14.5 6 2 **
LPS 1 IFN-γ 1 MDP(Lys)GDP (100) 11 6 1.4 ** 11.5 6 6.3 **
aMurine elicited peritoneal macrophages were incubated with MDP(Lysyl)GDP (1–
100 µg per ml) for 1 h followed by addition of LPS, IFN-γ, and LPS 1 IFN-γ.
bMDP(Lysyl)GDP was added simultaneously with LPS, IFN-γ, and LPS 1 IFN-γ into
the cell culture.
cAfter 24 h of incubation, supernatant was used to estimate nitrite accumulation by the
Griess method. Nitrite data are representative of means 6 SD, as determined by Student’s
t test, for three independent experiments. **p , 0.01; ***p , 0.001.
has an anti-inflammatory activity. It specifically inhibited the activation
of murine macrophages by LPS to induce iNOS and therefore to
generate nitrite in culture supernatants. Concomitantly, the production
of macrophage-derived proinflammatory cytokines, IL-1β, and TNF-α
was also significantly suppressed in a dose-dependent manner. In the
Table II. Anti-inflammatory activity of MDP(Lysyl)GDP on
TPA-induced ear inflammation
Pinnal weight in mg
Treatment (mean 6 SD)a % Inhibitionb
Topical, µg per ear
vehicle 31.9 6 4.5 (n 5 16)
MDP(Lysyl)GDP, 1 3 33 30.4 6 4.6 (n 5 16) 5 n.s.
MDP(Lysyl)GDP, 1 3 100 24.4 6 5.6 (n 5 16) 24***
MDP(Lysyl)GDP, 1 3 330 13.6 6 6.3 (n 5 16) 57***
Oral, mg per kg
vehicle 31.8 6 2.6 (n 5 16)
MDP(Lysyl)GDP, 3 3 50 31.4 6 2.4 (n 5 16) 1 n.s.
Topical, µg per ear
vehicle 30.0 6 3.0 (n 5 8)
Dexamethasone, 1 3 1.2 17.5 6 2.9 (n 5 8) 42**
Dexamethasone, 1 3 12 5.3 6 2.7 (n 5 8) 83***
aMean pinnal weight 6 SD; n, total number of animals used.
bPercentage inhibition of edema relative to vehicle-treated animals. **p , 0.01;
***p , 0.001; n.s., not significant.
presence of MDP(Lysyl)GDP, macrophages activated by LPS expressed
less steady-state mRNA transcripts for and secreted significantly less
amounts of IL-1β, TNF-α, and iNOS as compared with LPS-activated
cells alone. The water soluble MDP(Lysyl)GDP was by itself not capable
of activating the macrophages to produce inflammatory cytokines or
NO. The inhibitory effect of MDP(Lysyl)GDP appeared to be specific
to LPS-mediated macrophage activation. Further proof for this conten-
tion was provided by the synergy we observed between MDP(Lys-
yl)GDP and IFN-γ in the activation of the macrophages to produce
NO. The mechanisms for the synergy are unclear. Drapier et al (1988)
showed that the parent MDP molecule synergized with IFN-γ in the
activation of macrophages to produce NO in a manner that was
partially inhibitable by anti-TNF-α antibody. It was proposed that the
TNF-α produced acted in a feedback loop to activate IFN-γ-primed
cells so as to increase the amounts of NO. It is therefore possible that
MDP(Lysyl)GDP, although lacking toxic synergism with LPS, has
retained the ability of the parent molecule to synergize with IFN-γ in
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Table III. Anti-inflammatory activity of MDP(Lysyl)GDP
expressed as inhibition of pinnal edema after oral and topical
treatment in allergic contact dermatitis
Pinnal weight in mg
Treatment (mean 6 SD)a % Inhibitionb
Oral, mg per kg
vehicle 24.5 6 3.6 (n 5 16)
MDP(Lysyl)GDP, 3 3 50 16.9 6 3.6 (n 5 16) 31**
Topical, µg per ear
vehicle 27.6 6 5.6 (n 5 24)
MDP(Lysyl)GDP, 1 3 33 27.2 6 4.7 (n 5 24) 2 n.s.
MDP(Lysyl)GDP, 1 3 100 19.2 6 4.8 (n 5 16) 31**
MDP(Lysyl)GDP, 1 3 330 15.5 6 5.4 (n 5 24) 44**
Topical, µg per ear
vehicle 28.9 6 5.9 (n 5 8)
Dexamethasone, 1 3 0.4 23.0 6 11.4 (n 5 8) 21 n.s
Dexamethasone, 1 3 1.2 16.7 6 5.6 (n 5 16) 44***
Dexamethasone, 1 3 3 14.2 6 7.1 (n 5 24) 51***
Dexamethasone, 1 3 12 9.4 6 4.2 (n 5 24) 68***
aMean difference in pinnal weights (mg) 6 SD; n, total number of animals used.
bPercentage inhibition of edema relative to vehicle-treated animals. **p , 0.01;
***p , 0.001; n.s., not significantly different from controls.
the induction of TNF-α and other factors required for the synergy.
Identification of the factors responsible for the synergy must await
further study. It is clear, however, that LPS and IFN-γ act through
totally separate receptors and therefore induce the transcription of
different genes. As several cytokine genes contain responsive elements
for both LPS and IFN-γ, it is possible that cross-talks occur between
the LPS and IFN-γ signaling transduction pathways downstream from
the receptors, as supported by the frequently observed synergy between
the two stimuli (Martin et al, 1994). It is therefore quite possible that
if MDP(Lysyl)GDP interferes with the LPS signaling transduction
pathway it will also affect the cross-talks that usually occur between
the two signaling pathways.
Our findings that a derivative of MDP antagonizes LPS induced
effects differ from several reports in the literature showing that the
parent MDP molecule can synergize with LPS in the activation of
macrophages (Vermeulen et al, 1987; Palacios et al, 1992; Shi et al,
1995). For example, Palacios et al (1992) showed that MDP activated
murine lung and thioglycollate-elicited peritoneal macrophages to
produce inflammatory mediators. In the presence of LPS, however, the
production of the inflammatory mediators was significantly upregulated,
suggesting that there was synergism between LPS and the MDP
molecule in the activation of the cells. Similarly, stimulation of canine
monocytes with MDP and LPS resulted in synergistic activation of
cells as measured by IL-6 production (Shi et al, 1995). A similar picture
was seen in human monocytes where MDP was found to synergize
with LPS in the induction of mRNA accumulation of IL-1 (Vermeulen
et al, 1987). Thus, the mechanism of the interactions between MDP
and LPS could be mediated, at least in part, at the level of cytokine
gene transcription. Moreover, expression of cytokines is regulated by
common transcription factor NF-κB that is regulated by TNF-α and
IL-1 (Krasnow et al, 1991). Furthermore, the nonpyrogenic derivative
MDP(Threonyl)GDP, but not the parent molecule MDP, was found
to lack the ability of activating the cellular transcription factor NF-κB
(Schreck et al, 1992). In our study, MDP(Lysyl)GDP downregulated
LPS-induced TNF-α and IL-1β, suggesting that MDP(Lysyl)GDP
exerts its activity through downregulation of a common transcription
factor. Thus, it is possible to attribute the biologic activities of muramyl
peptides to differential effects on cytokine gene transcription and
activation of cellular transcription factors.
The inhibitory effect of MDP(Lysyl)GDP on the production of
macrophage-derived inflammatory mediators was not only an in vitro
phenomenon. Application of TPA onto the ears of mice leads to acute
inflammation with maximal ear swelling occurring at 6 h. Topical
pretreatment of the animals with single doses of MDP(Lysyl)GDP 30
min before TPA application resulted in a significant and a dose-
dependent suppression of the ear inflammation. No protective effect
of MDP(Lysyl)GDP was observed when the compound was adminis-
tered by the oral route 3, 2, and 1 d prior to the application of TPA.
The lack of efficacy of orally administered MDP(Lysyl)GDP against
TPA-induced ear inflammation was presumably due to the failure of
the derivative to achieve an effective concentration at the involved ear
site. MDP(Lysyl)GDP was also effective in the oxazolone-induced ear
inflammation. In this model, mice are sensitized by painting the shaved
abdomen with oxazolone. Seven days later, the animals are challenged
by applying the hapten onto the ears. Maximal ear swelling occurs at
24 h following hapten challenge, a time period in which several
proinflammatory cytokines are produced (Kondo et al, 1994; Ohmen
et al, 1995; Werfel et al, 1996). Administration of MDP(Lysyl)GDP to
oxazolone-sensitised mice either orally at 50 mg per kg on days 3, 2,
and 1 prior to oxazolone challenge or topically at 33, 100, and 330 µg
per ear site 30 min after the oxazolone challenge, significantly suppressed
ear inflammation (p , 0.001). These findings show that the in vivo
anti-inflammatory activity of MDP(Lysyl)GDP is mediated at the level
of elicitation of contact hypersensitivity and are consistent with the
work of Parant et al (1995) and Adeleye et al (1994), who used other
derivatives of MDP. In the study of Parant et al (1995), two hydrophilic
derivatives of MDP, murabutide and murametide, which also lacked
toxic synergism with LPS, were found to protect galactosamine-
sensitized mice from an otherwise lethal endotoxemia. The protective
effects of the MDP derivatives were attributed to their inability to
prime macrophages for enhanced cytokine induction. Direct evidence
for the inhibition of the production of TNF-α and IL-1α by a MDP
derivative, GMDP, was provided by the work of Adeleye et al (1994).
They showed that animals presensitized to LPS by infection with
Corynebacterium parum given GMDP produced significantly less TNF-
α and IL-1α following an intravenous challenge with LPS. Our
findings extend these observations by showing that NO, besides IL-
1β and TNF-α, plays a major role in acute and chronic inflammation.
Earlier reports from Ialenti et al (1992) and McCartney-Francis et al
(1993) have shown that administration of inhibitors of NOS decreased,
whereas L-arginine enhanced the extent of the lesions in a model of
both acute inflammation (Ialenti et al, 1992) and chronic adjuvant
arthritis in rats (McCartney-Francis et al, 1993). More recently, Morita
et al (1996) showed that NO was involved in the late phase of contact
hypersensitivity in mice. Hence, treatment of mice undergoing picric
chloride-induced hypersensitivity reaction with an inhibitor of NOS,
L-NAME, led to a significant decrease in the production of IL-2 and
IFN-γ in the draining lymph nodes and inhibition of ear inflammation.
The mechanism(s) by which MDP(Lysyl)GDP inhibited the synthesis
of such inflammatory mediators by LPS-activated macrophages and
protected mice from both animal models of contact irritant and contact
allergen, are unclear. We envisage several potential explanations for
these results. First, there are reports showing that chemical modification
of MDP can result in either enhancement or reversal of its toxic
synergism with LPS (Adeleye et al, 1994; Parant et al, 1995). In this
regard, Adeleye et al (1994) examined the ability of MDP and seven
of its analogs to counteract the toxic actions of LPS. They found that
GMDP, threonylMDP, GMDPBenz, and GMDPOBut were able to
reduce the level of primary cytokines induced by LPS, whereas MDP
increased the levels of such cytokines.
Lastly, MDP(Lysyl)GDP might have exerted its in vivo effect through
the inhibition of an NO-dependent pathway. This pathway has been
shown to be an important event in the release of the inflammatory
cytokines by cells in vitro and in vivo. Indeed, NO was shown to
directly induce the in vitro release of inflammatory cytokines such as
TNF-α, IL-6, and IL-8 (Eigler et al, 1993; Becherel et al, 1994;
Andrew et al, 1995; Zinetti et al, 1995) and to synergize with the
released cytokines in the induction of other inflammatory mediators.
It does not, therefore, come as a surprise that inhibition of NO
production by MDP(Lysyl)GDP was associated with a marked anti-
inflammatory effect. Taken together, our results suggest that MDP(Lys-
yl)GDP might be a novel alternative for therapy in allergic and
inflammatory skin diseases.
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